A Phase IIb Study of RGX-314 to Treat Wet Age-Related Macular Degeneration (wet AMD)
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs RGX 314 (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 05 Nov 2019 According to a REGENXBIO media release, the company anticipates a short delay in initiating this study, following notification from the FDA regarding certain third-party commercially-available surgical devices that were used to deliver RGX-314 in the Phase I/IIa trial. The company plans working with the FDA to address this matter, and as a result, the company plans to initiate this study in the first quarter of 2020.
- 05 Nov 2019 According to a REGENXBIO media release, the study will commence in the first quarter of 2020.
- 04 Sep 2019 According to a REGENXBIO media release, this trial is expected to begin by the end of 2019.